Rivaroxaban with the brand name Xarelto is an anticoagulant which is developed by Bayer/ Johnson & Johnson. It is commonly used for dissolving or preventing a type of blood clot that is called deep vein thrombosis (DVT) by blocking the activity of certain clotting substances in the blood.
Apixaban with the trade name Eliquis is an orally active, reversible, selective factor Xa inhibitor. Specialist indicates this medication for the treatment of venous thromboembolic events that are taken by mouth.
This anticoagulant prevents thrombin generation and thrombus formation; it decreases the conversion of prothrombin to thrombin. After approval in 2012, Pfizer and Bristol-Myers Squibb developed Apixaban in a joint venture. Apixaban is the third novel oral anticoagulant approved in the U.S. for the management of thromboembolic disease.
No account yet?
Create an Account
